Roche/Chugai’s RoActemra should be routinely offered throughout the NHS to adults with giant cell arteritis (GCA) within the next three months, following a final green light from cost regulators.Original Article
You may also like
Nouscom to present re‑treatment data in Lynch...
ViiV Healthcare to unveil new HIV treatment data at...
Almirall’s paediatric registration of Ebglyss for...
The Bloc appoints Jon Chapman as European Executive...
UCSD, IGI Partnership Expands CRISPR Innovation Across...
10x Clinical Expansion Advances with CLIA Lab Plans...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.